PMID- 30888989
OWN - NLM
STAT- MEDLINE
DCOM- 20190520
LR  - 20190520
IS  - 1536-0229 (Electronic)
IS  - 0363-9762 (Linking)
VI  - 44
IP  - 5
DP  - 2019 May
TI  - Safety, Biodistribution, and Dosimetry of 123I-6-Deoxy-6-Iodo-D-Glucose, a Tracer 
      of Glucose Transport, in Healthy and Diabetic Volunteers.
PG  - 386-393
LID - 10.1097/RLU.0000000000002510 [doi]
AB  - PURPOSE: Insulin resistance is a key feature of the metabolic syndrome and type 2 
      diabetes, in which noninvasive assessment is not currently allowed by any 
      methodology. We previously validated an iodinated tracer of glucose transport 
      (6DIG) and a new methodology for the in vivo quantification of cardiac insulin 
      resistance in rodents. The aim of this study was to investigate the safety, 
      biodistribution, and radiation dosimetry of this method using I-6DIG in 5 healthy 
      and 6 diabetic volunteers. METHODS: The collection of adverse effects (AEs) and 
      medical supervision of vital parameters and biological variables allowed the 
      safety evaluation. Biodistribution was studied by sequentially acquiring 
      whole-body images at 1, 2, 4, 8, and 24 hours postinjection. The total number of 
      disintegrations in each organ normalized to the injected activity was calculated 
      as the area under the time-activity curves. Dosimetry calculations were performed 
      using OLINDA/EXM. RESULTS: No major adverse events were observed. The average 
      dose corresponding to the 2 injections of I-6DIG used in the protocol was 182.1 +/- 
      7.5 MBq. A fast blood clearance of I-6DIG was observed. The main route of 
      elimination was urinary, with greater than 50% of urine activity over 24 hours. 
      No blood or urine metabolite was detected. I-6DIG accumulation mostly occurred in 
      elimination organs such as kidneys and liver. Mean radiation dosimetry 
      calculations indicated an effective whole-body absorbed dose of 3.35 +/- 0.57 mSv 
      for the whole procedure. CONCLUSIONS: I-6DIG was well tolerated in human with a 
      dosimetry profile comparable to that of other commonly used iodinated tracers, 
      thereby allowing further clinical development of the tracer.
FAU - Calizzano, Alex
AU  - Calizzano A
FAU - Perret, Pascale
AU  - Perret P
FAU - Desruet, Marie-Dominique
AU  - Desruet MD
FAU - Ahmadi, Mitra
AU  - Ahmadi M
FAU - Reboulet, Ghislaine
AU  - Reboulet G
AD  - Department of Nuclear Medicine, CHU Grenoble Alpes, Grenoble, France.
FAU - Djaileb, Loic
AU  - Djaileb L
FAU - Vanzetto, Gerald
AU  - Vanzetto G
FAU - Fagret, Daniel
AU  - Fagret D
FAU - Barone-Rochette, Gilles
AU  - Barone-Rochette G
FAU - Ghezzi, Catherine
AU  - Ghezzi C
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Clin Nucl Med
JT  - Clinical nuclear medicine
JID - 7611109
RN  - 0 (6-deoxy-6-iodoglucose)
RN  - 0 (Radiopharmaceuticals)
RN  - 9G2MP84A8W (Deoxyglucose)
SB  - IM
MH  - Adult
MH  - Deoxyglucose/administration & dosage/adverse effects/*analogs & 
      derivatives/pharmacokinetics
MH  - Diabetes Mellitus, Type 2/*diagnostic imaging
MH  - Female
MH  - Humans
MH  - Male
MH  - Radiation Dosage
MH  - Radiopharmaceuticals/administration & dosage/adverse effects/*pharmacokinetics
MH  - Renal Elimination
MH  - Tissue Distribution
EDAT- 2019/03/20 06:00
MHDA- 2019/05/21 06:00
CRDT- 2019/03/20 06:00
PHST- 2019/03/20 06:00 [pubmed]
PHST- 2019/05/21 06:00 [medline]
PHST- 2019/03/20 06:00 [entrez]
AID - 10.1097/RLU.0000000000002510 [doi]
PST - ppublish
SO  - Clin Nucl Med. 2019 May;44(5):386-393. doi: 10.1097/RLU.0000000000002510.